Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer

Cancer Science

Volumn 102, Issue 2, 2011, Pages 324-329

  Miyazaki, Akihiro ^a   Kobayashi, Junichi ^a   Torigoe, Toshihiko ^a   Hirohashi, Yoshihiko ^a   Yamamoto, Takashi ^a   Yamaguchi, Akira ^a   Asanuma, Hiroko ^a   Takahashi, Akari ^a   Michifuri, Yoshitaka ^a   Nakamori, Kenji ^a   Nagai, Itaru ^a   Sato, Noriyuki ^a   Hiratsuka, Hiroyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA A24 ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; SURVIVIN 2B80 88; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE INDURATION; INJECTION SITE PAIN; LIVER TOXICITY; LUNG METASTASIS; MALE; MOUTH CANCER; NEPHROTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; VACCINES, SUBUNIT;

EID: 79952080731     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01789.x     Document Type: Article

References (26)

1. Rodrigues VC, Moss SH, Tuomainen H. Oral cancer in the UK: to screen or not to screen. Oral Oncol 1998; 34: 454-65.
2. Yao M, Epstein JB, Modi BJ et al. Current surgical treatment of squamous cell cacinoma of the head and neck. Oral Oncol 2007; 43: 213-23.
3. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
4. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994; 91: 3515-19.
5. Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94: 805-18.
6. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, surviving, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
9. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-9.
10. Asanuma H, Torigoe T, Kamiguchi K et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptorvia phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005; 65: 11018-25.
11. Lo Muzio L, Pannone G, Staibano S et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003; 89: 2244-8.
12. Kawasaki H, Altieri DC, Lu CD et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071-4.
13. Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95: 92-5.
14. Lo Muzio L, Farina A, Rubini C et al. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005; 225: 27-33.
15. Rosato A, Pivetta M, Parenti A et al. An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 2006; 119: 1717-22.
16. Tanaka K, Iwamoto S, Gon G et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-34.
17. Freier K, Pungs S, Sticht C et al. High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Int J Cancer 2007; 120: 942-6.
18. Hirohashi Y, Torigoe T, Maeda A et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9.
19. Idenoue S, Hirohashi Y, Torigoe T et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005; 11: 1474-82.
20. Kobayashi J, Torigoe T, Hirohashi Y et al. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. J Transl Med 2009; 7: 1.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
22. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94.
23. Sato Y, Sahara H, Tsukahara T et al. Improved generation of HLA class I/peptide tetramers. J Immunol Methods 1996; 20: 177-84.
24. Sato Y, Nabeta Y, Tsukahara T et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002; 169: 1611-18.
25. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19.
26. Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008; 6: 24.